|

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

RECRUITINGSponsored by Wake Forest University Health Sciences
Actively Recruiting
SponsorWake Forest University Health Sciences
Started2025-04-09
Est. completion2027-07
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT06580106

Summary

The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Written informed consent and HIPAA authorization for release of personal health information.
* Age ≥ 18 years of age at the time of enrollment
* Confirmed diagnosis of AML
* Planned initial treatment with azacitidine and venetoclax
* Ability to read and understand the English and/or Spanish language
* As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study

Exclusion Criteria:

* None

Conditions2

CancerLeukemia, Myeloid, Acute

Locations2 sites

Levine Cancer Institute
Charlotte, North Carolina, 28204
Courtney Schepel(980) 292-0817courtney.schepel@advocatehealth.org
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157
Timothy Pardee, MD336-716-2466tspardee@wakehealth.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.